CA3228366A1 - Engineered high fidelity omni-50 nuclease variants - Google Patents
Engineered high fidelity omni-50 nuclease variants Download PDFInfo
- Publication number
- CA3228366A1 CA3228366A1 CA3228366A CA3228366A CA3228366A1 CA 3228366 A1 CA3228366 A1 CA 3228366A1 CA 3228366 A CA3228366 A CA 3228366A CA 3228366 A CA3228366 A CA 3228366A CA 3228366 A1 CA3228366 A1 CA 3228366A1
- Authority
- CA
- Canada
- Prior art keywords
- omni
- amino acid
- nuclease
- variant
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232571P | 2021-08-12 | 2021-08-12 | |
| US63/232,571 | 2021-08-12 | ||
| US202263332214P | 2022-04-18 | 2022-04-18 | |
| US63/332,214 | 2022-04-18 | ||
| US202263333037P | 2022-04-20 | 2022-04-20 | |
| US63/333,037 | 2022-04-20 | ||
| PCT/US2022/074930 WO2023019263A1 (en) | 2021-08-12 | 2022-08-12 | Engineered high fidelity omni-50 nuclease variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3228366A1 true CA3228366A1 (en) | 2023-02-16 |
Family
ID=85201002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3228366A Pending CA3228366A1 (en) | 2021-08-12 | 2022-08-12 | Engineered high fidelity omni-50 nuclease variants |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250283115A1 (https=) |
| EP (1) | EP4384609A4 (https=) |
| JP (1) | JP2024531217A (https=) |
| KR (1) | KR20240043792A (https=) |
| AU (1) | AU2022326575A1 (https=) |
| CA (1) | CA3228366A1 (https=) |
| IL (1) | IL310730A (https=) |
| WO (1) | WO2023019263A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| KR20230142740A (ko) | 2021-02-08 | 2023-10-11 | 에멘도바이오 인코포레이티드 | Omni-103 crispr 뉴클레아제 |
| CN119546757A (zh) | 2022-05-25 | 2025-02-28 | 宏基因组学公司 | 肝酶表达的补充 |
| US20260021141A1 (en) * | 2022-07-15 | 2026-01-22 | Emendobio Inc. | Strategies For Knock-Ins At APLP2 Safe Harbor Sites |
| WO2025117858A1 (en) * | 2023-11-28 | 2025-06-05 | Metagenomi, Inc. | Supplementation of liver enzyme expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512446B1 (en) * | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2020223514A2 (en) * | 2019-04-30 | 2020-11-05 | Emendobio Inc. | Novel omni-50 crispr nuclease |
| WO2020223553A2 (en) * | 2019-04-30 | 2020-11-05 | Emendobio Inc. | Novel omni crispr nucleases |
| US12435334B2 (en) * | 2019-11-06 | 2025-10-07 | Emendobio Inc. | Differential knockout of an allele of a heterozygous ELANE gene-II |
| WO2024168159A1 (en) * | 2023-02-08 | 2024-08-15 | Emendobio Inc. | Engineered omni-50 nuclease variants |
-
2022
- 2022-08-12 IL IL310730A patent/IL310730A/en unknown
- 2022-08-12 CA CA3228366A patent/CA3228366A1/en active Pending
- 2022-08-12 AU AU2022326575A patent/AU2022326575A1/en active Pending
- 2022-08-12 US US18/682,982 patent/US20250283115A1/en active Pending
- 2022-08-12 JP JP2024508545A patent/JP2024531217A/ja active Pending
- 2022-08-12 EP EP22856846.5A patent/EP4384609A4/en active Pending
- 2022-08-12 WO PCT/US2022/074930 patent/WO2023019263A1/en not_active Ceased
- 2022-08-12 KR KR1020247007872A patent/KR20240043792A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240043792A (ko) | 2024-04-03 |
| AU2022326575A1 (en) | 2024-03-14 |
| JP2024531217A (ja) | 2024-08-29 |
| IL310730A (en) | 2024-04-01 |
| WO2023019263A1 (en) | 2023-02-16 |
| EP4384609A1 (en) | 2024-06-19 |
| EP4384609A4 (en) | 2025-07-02 |
| US20250283115A1 (en) | 2025-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240226246A9 (en) | Novel omni-50 crispr nuclease | |
| US20250283115A1 (en) | Engineered high fidelity omni-50 nuclease variants | |
| US20220213456A1 (en) | Novel omni crispr nucleases | |
| US11946077B2 (en) | OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR nucleases | |
| JP2020536502A (ja) | 遺伝子操作のためのヌクレアーゼシステム | |
| US20250034596A1 (en) | Omni-103 CRISPR Nuclease-RNA Complexes | |
| US20250011740A1 (en) | Novel omni 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 crispr nucleases | |
| US20240425885A1 (en) | OMNI 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 CRISPR NUCLEASE | |
| US12529043B2 (en) | OMNI-103 CRISPR nuclease | |
| US20240002840A1 (en) | Novel omni-50 crispr nuclease-rna complexes | |
| US20250043260A1 (en) | Engineered High Activity Omni-79 Nuclease Variants | |
| EP3935165A1 (en) | Mesophilic argonaute systems and uses thereof | |
| US20250011741A1 (en) | Omni 263, 264, 266, 268, 269, 271, 274, 275, 276, 278, 279, 280, 281, 283, 284, 286, 287, 288, 290, 291, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 329, 330, 331, 332, 333, 334, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 375, 376, | |
| US20240376453A1 (en) | Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases | |
| US20230383273A1 (en) | Novel omni 56, 58, 65, 68, 71, 75, 78, and 84 crispr nucleases | |
| IL322528A (en) | Engineered variants of omni-50 nuclease | |
| US12091688B2 (en) | OMNI-103 CRISPR nuclease | |
| IL321775A (en) | Omni-335 crispr nuclease | |
| CN118176295A (zh) | 工程化高保真度omni-50核酸酶变体 | |
| HK40112369A (zh) | 工程化高保真度omni-50核酸酶变体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240719 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240802 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240802 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250808 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |